Medical technology company Vivos Therapeutics Inc, which makes the Vivos System oral appliances and protocols for mild-to-moderate obstructive sleep apnea (OSA), will launch a new telemedicine service called MyoCorrect. On MyoCorrect, trained therapists will provide Vivos-trained providers access to orofacial myofunctional therapy (OMT) via telemedicine technology as a component to OSA treatment using the company’s Vivos System.
Vivos expects to see additional revenue from the MyoCorrect service in the form of increased Vivos System cases and fees charged for the service. Vivos believes the MyoCorrect service will become an important value-added component in the treatment of OSA using the Vivos System. Vivos further believes that offering orofacial myofunctional therapy as a service will provide Vivos with an additional competitive advantage in the OSA treatment marketplace.
OMT therapists work to strengthen and improve function in the muscles of the lips, tongue, cheeks and face and their related roles in breathing, sucking, chewing, swallowing, and some aspects of speech. Vivos plans to make the MyoCorrect protocol available as a component of the Vivos System and will actively integrate training and implementation protocols for Vivos trained dentists to utilize the MyoCorrect therapy.
Vivos-trained dentists who have actively incorporated OMT into their Vivos System treatment protocols report four primary benefits:
- higher case acceptance,
- better patient compliance,
- shorter treatment times, and
- improved clinical outcomes.
But due to scarcity of trained orofacial myofunctional therapy therapists in many areas and other factors, many dentists and patients have been unable to access this adjunctive therapy. MyoCorrect will provide every Vivos dentist with immediate access via telemedicine to this clinical resource.
“The launch of this new service is an important step for Vivos as we continue to offer what we believe are the best therapeutic options available for patients who suffer from sleep-disordered breathing and the most prevalent forms of obstructive sleep apnea. We believe we will be able to leverage our current infrastructure and growing dentist network for rapid deployment and adoption of the MyoCorrect OMT therapy,” says Kirk Huntsman, Vivos’ chairman and CEO, in a release. “As Vivos-trained dentists come to experience the ways in which OMT can enhance their Vivos System case outcomes, we expect the adoption rate of MyoCorrect as an integral part of the Vivos System to rise. As that happens, the revenue contributions of MyoCorrect to Vivos in the form of increased Vivos System sales as well as fees charged for the OMT service could be significant.
“We look forward to rolling out MyoCorrect across our network in the coming months. We believe this clinical enhancement to our flagship Vivos System treatment for mild-to-moderate OSA will work synergistically within the emerging Vivos dental sleep medicine ecosystem. This ecosystem features extensive clinical training through the Institute for Craniofacial Sleep Medicine, Vivos AireO2 practice management software, Vivos Airway Intelligence Services, Vivos Billing Intelligence Services, VivoScore diagnostic devices powered by SleepImage, our proprietary Vivos System oral appliance therapy, and multidisciplinary collaboration between physicians and Vivos dentists through the growing network of Vivos-trained dentist offices and Pneusomnia clinics.”
The launch of MyoCorrect follows the acquisition by Vivos of certain assets from and the entry into related agreements with MyoCorrect LLC and its affiliates. MyoCorrect LLC is a healthcare provider based in New York that specializes in the delivery of orofacial myofunctional therapy via telemedicine.